Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
前收盘价
US$319.12
−US$0.89 · -0.28%
盘中时间采用ET。市场数据可能有所延迟。
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
日内区间
当前US$319.12
52周区间
当前US$319.12
盘中时间采用ET。市场数据可能有所延迟。
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
日内区间
当前US$319.12
52周区间
当前US$319.12
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 14.04亿 USD | 11.95亿 USD | 10.59亿 USD | 8.47亿 USD | 7.48亿 USD |
| 销货成本 | 4.61亿 USD | 4.4亿 USD | 3.76亿 USD | 3.12亿 USD | 2.72亿 USD |
| 毛利 | 9.42亿 USD | 7.55亿 USD | 6.83亿 USD | 5.35亿 USD | 4.75亿 USD |
| 研究与开发 | 8976.6万 USD | 9478.3万 USD | 8442.3万 USD | 7940.7万 USD | 1.05亿 USD |
| 销售、一般及管理费用 | 6.63亿 USD | 5.74亿 USD | 5.06亿 USD | 4.5亿 USD | 3.78亿 USD |
| 营业费用 | 7.53亿 USD | 6.69亿 USD | 6.09亿 USD | 5.29亿 USD | 4.83亿 USD |
| 利息收入 | 1629.4万 USD | 1369万 USD | 682.5万 USD | 188.6万 USD | 287.1万 USD |
| 利息支出 | 131.1万 USD | 141.8万 USD | 173.9万 USD | 174.9万 USD | 193.3万 USD |
| 折旧和摊销 | 1747.1万 USD | 2370.2万 USD | 2725.7万 USD | 2432.1万 USD | 1640.8万 USD |
| 营业利润 | 1.89亿 USD | 8622.4万 USD | 7355.1万 USD | 608.2万 USD | −750.1万 USD |
| 净利润 | 1.78亿 USD | 1401.2万 USD | 9095.4万 USD | −200.2万 USD | 528.4万 USD |
公司数据更新于 2026年11月22日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$320
上涨空间 0.28%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2014年11月16日 | 1:10 | — | — |
已生效 2014年11月16日
1:10
报告持有此股票敞口的交易所交易基金。
iShares Core S&P Mid-Cap ETFIJH4.53亿0.39%1150.6亿 USD0.05%US$68.60-2.68%
Vanguard Morningstar Total Stock Market ETFVTI2.99亿0.02%6893亿 USD0.03%US$340.02-3.52%
Vanguard Morningstar Small-Cap ETFVB2.68亿0.15%787亿 USD0.03%US$270.68-2.56%
Vanguard Morningstar Small-Cap Growth ETFVBK1.5亿0.35%225亿 USD0.05%US$298.35-3.85%
Vanguard Extended Market ETFVXF1.42亿0.15%302亿 USD0.05%US$211.44-3.21%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY9437.18万0.38%245.19亿 USD0.23%US$626.03-2.64%
iShares S&P Mid-Cap 400 Growth ETFIJK7757.3万0.81%95.96亿 USD0.16%US$99.99-3.36%
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMD6935.56万0.38%180.58亿 USD0.03%US$60.11-2.66%
iShares Core S&P Mid-Cap ETFIJH
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
State Street SPDR S&P MIDCAP 400 ETF TrustMDY
iShares S&P Mid-Cap 400 Growth ETFIJK
State Street SPDR Portfolio S&P 400 Mid Cap ETFSPMDAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。